Comparison of the Alzheimer's disease assessment scale cognitive subscale and the vascular dementia assessment scale in differentiating elderly individuals with different degrees of white matter changes - The LADIS study

被引:35
作者
Ylikoski, Raija
Jokinen, Hanna
Andersen, Pia
Salonen, Oili
Madureira, Sofia
Ferro, Jose
Barkhof, Frederik
van der Flier, Wiesje
Schmidt, Reinhold
Fazekas, Franz
Scheltens, Philip
Waldemar, Gunhild
Salvadori, Emilia
Pantoni, Leonardo
Inzitari, Domenico
Erkinjuntti, Timo
机构
[1] Univ Helsinki, Dept Neurol, Memory Res Unit, FI-00029 Helsinki, Finland
[2] Univ Helsinki, Dept Psychol, FI-00029 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Helsinki Med Imaging Ctr, Helsinki, Finland
[4] Hosp Santa Maria, Ctr Estudos Egas Moniz, Serv Neurol, Lisbon, Portugal
[5] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands
[6] Vrije Univ Amsterdam, Med Ctr, Image Anal Ctr, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands
[8] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands
[9] Med Univ, Dept Neurol, Graz, Austria
[10] Med Univ, MRI Inst, Graz, Austria
[11] Univ Copenhagen Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark
[12] Univ Florence, Dept Neurol & Psychiat Sci, Florence, Italy
关键词
cognition; neuropsychology; white matter changes; Vascular Dementia Assessment Scale cognitive subscale;
D O I
10.1159/000103865
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Aims: The Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) is a widely used rating instrument. The Vascular Dementia Assessment Scale cognitive subscale (VADAS-cog) includes additional tests reflecting mental speed and executive functions. The objective of this study was to compare the results of the two scales among subjects with various degrees of white matter hyperintensities (WMHs). Methods: In the multicentre, multinational Leukoaraiosis and Disability in the Elderly (LADIS) study, 616 non-disabled subjects between the ages of 65 and 84 were examined using MRI, the ADAS-cog and VADAS-cog. The WMH rating from the MRI divided the patients into groups of mild (n = 280), moderate ( n = 187) and severe ( n = 149) degrees of change. Results: Covariance analysis controlling for the effect of age and education revealed that the ADAS-cog differentiated only the mild and severe WMH groups, while the differences between all three groups were highly significant with the VADAS-cog. Conclusions: The VADAS-cog significantly differentiated between all the white matter groups. In comparison, the ADAS-cog differentiated only severe changes. Accordingly, the VADAS-cog may be a more sensitive endpoint in studies of patients with white matter load and vascular burden of the brain. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 41 条
[1]  
[Anonymous], 2004, Neuropsychological Assessment
[2]  
Burges P. W., 1997, Methodology of frontal and executive function, P81, DOI DOI 10.1024//1016-264X.10.2.123
[3]  
Cronbach L.J., 1984, ESSENTIALS PSYCHOL T
[4]   THE EFFECT OF WHITE-MATTER HYPERINTENSITY VOLUME ON BRAIN STRUCTURE, COGNITIVE PERFORMANCE, AND CEREBRAL METABOLISM OF GLUCOSE IN 51 HEALTHY-ADULTS [J].
DECARLI, C ;
MURPHY, DGM ;
TRANH, M ;
GRADY, CL ;
HAXBY, JV ;
GILLETTE, JA ;
SALERNO, JA ;
GONZALESAVILES, A ;
HORWITZ, B ;
RAPOPORT, SI ;
SCHAPIRO, MB .
NEUROLOGY, 1995, 45 (11) :2077-2084
[5]   The Alzheimer's disease assessment scale: Evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease [J].
Doraiswamy, PM ;
Kaiser, L ;
Bieber, F ;
Garman, RL .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2001, 15 (04) :174-183
[6]   Rivastigmine for dementia associated with Parkinson's disease [J].
Emre, M ;
Aarsland, D ;
Albanese, A ;
Byrne, EJ ;
Deuschl, G ;
De Deyn, PP ;
Durif, F ;
Kulisevsky, J ;
van Laar, T ;
Lees, A ;
Poewe, W ;
Robillard, A ;
Rosa, MM ;
Wolters, E ;
Quarg, P ;
Tekin, S ;
Lane, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2509-2518
[7]   An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia [J].
Erkinjuntti, T ;
Kurz, A ;
Small, GW ;
Bullock, R ;
Lilienfeld, S ;
Damaraju, CV .
CLINICAL THERAPEUTICS, 2003, 25 (06) :1765-1782
[8]   Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial [J].
Erkinjuntti, T ;
Kurz, A ;
Gauthier, S ;
Bullock, R ;
Lilienfeld, S ;
Damaraju, CV .
LANCET, 2002, 359 (9314) :1283-1290
[9]   Differential qualitative responses to rivastigmine in APOE ε4 carriers and noncarriers [J].
Farlow, M ;
Lane, R ;
Kudaravalli, S ;
He, Y .
PHARMACOGENOMICS JOURNAL, 2004, 4 (05) :332-335
[10]   Impact of APOE in mild cognitive impairment [J].
Farlow, MR ;
He, Y ;
Tekin, S ;
Xu, J ;
Lane, R ;
Charles, HC .
NEUROLOGY, 2004, 63 (10) :1898-1901